KTTA - The Buzz Show: Pasithea Therapeutics Corp. (NASDAQ: KTTA) Surges Upon SPRAVATO Approval

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Pasithea Therapeutics Corp. Surges Upon SPRAVATO Approval ”

Pasithea Therapeutics Corp.  (NASDAQ: KTTA) surged over 196% in premarket trading after the company was approved to provide its esketamine nasal spray for treatment-resistant depression in adults.

Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer SPRAVATO® and has begun offering the treatment in its Knightsbridge, London location.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

For more information, please visit: Pasithea Therapeutics Corp. (NASDAQ: KTTA)

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Pasithea Therapeutics Corp. (NASDAQ: KTTA) Surges Upon SPRAVATO Approval first appeared on Financial Buzz .

For further details see: